As of close of business last night, Amicus Therapeutics Inc’s stock clocked out at $11.22, down -0.44% from its previous closing price of $11.27. In other words, the price has decreased by -$0.05 from its previous closing price. On the day, 1693140 shares were traded.
Ratios:
To gain a deeper understanding of FOLD’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.52 and its Current Ratio is at 2.88. In the meantime, Its Debt-to-Equity ratio is 2.78 whereas as Long-Term Debt/Eq ratio is at 2.73.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Morgan Stanley on December 19, 2023, Upgraded its rating to Overweight and sets its target price to $20 from $15 previously.
On September 09, 2022, Morgan Stanley started tracking the stock assigning a Equal-Weight rating and target price of $14.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Apr 01 ’24 when Campbell Bradley L sold 7,500 shares for $11.67 per share. The transaction valued at 87,496 led to the insider holds 886,654 shares of the business.
MCGLYNN MARGARET G sold 7,500 shares of FOLD for $100,500 on Mar 05 ’24. The Director now owns 59,289 shares after completing the transaction at $13.40 per share. On Mar 04 ’24, another insider, MCGLYNN MARGARET G, who serves as the Director of the company, sold 7,500 shares for $13.29 each. As a result, the insider received 99,675 and left with 59,289 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, FOLD now has a Market Capitalization of 3.31B and an Enterprise Value of 3.47B. For the stock, the TTM Price-to-Sale (P/S) ratio is 8.30 while its Price-to-Book (P/B) ratio in mrq is 20.57. Its current Enterprise Value per Revenue stands at 8.70 whereas that against EBITDA is -37.72.
Stock Price History:
Over the past 52 weeks, FOLD has reached a high of $14.57, while it has fallen to a 52-week low of $9.70. The 50-Day Moving Average of the stock is 12.46, while the 200-Day Moving Average is calculated to be 12.31.
Shares Statistics:
It appears that FOLD traded 3.05M shares on average per day over the past three months and 2.48M shares per day over the past ten days. A total of 293.59M shares are outstanding, with a floating share count of 286.56M. Insiders hold about 2.99% of the company’s shares, while institutions hold 106.65% stake in the company. Shares short for FOLD as of Mar 15, 2024 were 32.4M with a Short Ratio of 10.64, compared to 26.78M on Feb 15, 2024. Therefore, it implies a Short% of Shares Outstanding of 10.97% and a Short% of Float of 11.02%.
Earnings Estimates
As of right now, 9 analysts gave their recommendation on the stock of the company. On average, analysts expect EPS of -$0.06 for the current quarter, with a high estimate of -$0.03 and a low estimate of -$0.08, while EPS last year was -$0.18. The consensus estimate for the next quarter is -$0.02, with high estimates of $0.01 and low estimates of -$0.04.
Analysts are recommending an EPS of between $0.18 and -$0.09 for the fiscal current year, implying an average EPS of $0. EPS for the following year is $0.4, with 9 analysts recommending between $0.62 and $0.17.
Revenue Estimates
In the current quarter, 10 analysts expect revenue to total $111.96M. It ranges from a high estimate of $115.04M to a low estimate of $107M. As of the current estimate, Amicus Therapeutics Inc’s year-ago sales were $83.08M, an estimated increase of 34.80% from the year-ago figure. For the next quarter, 10 analysts are estimating revenue of $125.77M, an increase of 33.10% less than the figure of $34.80% in the same quarter last year. There is a high estimate of $129.46M for the next quarter, whereas the lowest estimate is $122M.
A total of 11 analysts have provided revenue estimates for FOLD’s current fiscal year. The highest revenue estimate was $548.49M, while the lowest revenue estimate was $511M, resulting in an average revenue estimate of $531.19M. In the same quarter a year ago, actual revenue was $399.36M, up 33.00% from the average estimate. Based on 11 analysts’ estimates, the company’s revenue will be $682.06M in the next fiscal year. The high estimate is $798.27M and the low estimate is $618.98M. The average revenue growth estimate for next year is up 28.40% from the average revenue estimate for this year.
